Denver Nephrologists PC

1. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,290,522 9 payments
2. Akebia Therapeutics Inc $690,712 366 payments
3. Otsuka Pharmaceutical Co., Ltd. $430,522 37 payments
4. Boehringer Ingelheim Pharmaceuticals, Inc. $250,580 2 payments
5. CSL Behring $130,590 61 payments
6. Retrophin, Inc. $99,696 91 payments
7. Ardelyx, Inc. $1,800 1 payment
8. EMD Serono, Inc. $508 1 payment
9. Covidien LP $300 1 payment

1. A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy $460,494 3 payments
2. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (Dd-Ckd) (Inno2vate-Conversion) $305,381 16 payments
3. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of Vis649 in Participants With Immunoglobulin A (Iga) Nephropathy $265,018 30 payments
4. A Phase 2/3, Multicenter, Open-Label Trial to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy $259,373 3 payments
5. Phase II dose finding PoCC in CKD $250,580 2 payments
6. A Phase2b, Multicenter, Open-Label, Single-Arm Trial to Evaluate the Impact of Sibeprenlimab on Kidney Histopathology Through Repeat Kidney Biopsies in Adolescents and Adults With Immunoglobulin A Nephropathy $222,582 1 payment
7. A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy $198,961 1 payment
8. Akb-6548-Ci-0017 $189,601 204 payments
9. Phase II of VIS649 for IgA Nephropathy $165,504 7 payments
10. A Phase 2/3, Multicenter, Open-Label Trial to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy $149,113 1 payment

1. Other $78,098 76 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.